{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:06:51Z","timestamp":1767704811526,"version":"3.32.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.7759\/cureus.76702","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T05:44:08Z","timestamp":1735710248000},"source":"Crossref","is-referenced-by-count":2,"title":["Direct Oral Anticoagulants and Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Update on Evidence"],"prefix":"10.7759","author":[{"given":"Elrazi A","family":"Ali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Al-Sadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saja","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waail","family":"Rozi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutasim","family":"Idriss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky RA","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014, 124:2804-11. 10.1182\/blood-2014-02-522128","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1717","article-title":"Diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Parker C","year":"2005","unstructured":"Parker C, Omine M, Richards S, et al.. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005, 106:3699-709. 10.1182\/blood-2005-04-1717","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20525","article-title":"Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry","volume":"78","author":"Borowitz MJ","year":"2010","unstructured":"Borowitz MJ, Craig FE, Digiuseppe JA, et al.. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010, 78:211-30. 10.1002\/cyto.b.20525","journal-title":"Cytometry B Clin Cytom"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.208","article-title":"Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria","volume":"2016","author":"Parker CJ","year":"2016","unstructured":"Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2016, 2016:208-16. 10.1182\/asheducation-2016.1.208","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.6.1807","article-title":"Complement-mediated regulation of tissue factor activity in endothelium","volume":"182","author":"Saadi S","year":"1995","unstructured":"Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995, 182:1807-14. 10.1084\/jem.182.6.1807","journal-title":"J Exp Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-264051","article-title":"Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis","volume":"116","author":"Kourtzelis I","year":"2010","unstructured":"Kourtzelis I, Markiewski MM, Doumas M, et al.. Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood. 2010, 116:631-9. 10.1182\/blood-2010-01-264051","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2011.00262.x","article-title":"Paroxysmal nocturnal hemoglobinuria from bench to bedside","volume":"4","author":"Pu JJ","year":"2011","unstructured":"Pu JJ, Brodsky RA. Paroxysmal nocturnal hemoglobinuria from bench to bedside. Clin Transl Sci. 2011, 4:219-24. 10.1111\/j.1752-8062.2011.00262.x","journal-title":"Clin Transl Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13059","article-title":"Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus","volume":"101","author":"R\u00f6th A","year":"2018","unstructured":"R\u00f6th A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018, 101:3-11. 10.1111\/ejh.13059","journal-title":"Eur J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.342","article-title":"Anticoagulant therapy with rivaroxaban in a young patient\u00a0\u00a0with paroxysmal nocturnal hemoglobinuria","volume":"3","author":"Dragoni F","year":"2015","unstructured":"Dragoni F, Chiarotti F, Lombardi L, Iori AP, Cafolla A. Anticoagulant therapy with rivaroxaban in a young patient\u00a0\u00a0with paroxysmal nocturnal hemoglobinuria. Clin Case Rep. 2015, 3:790-2. 10.1002\/ccr3.342","journal-title":"Clin Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-018-0181-5","article-title":"Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events","volume":"16","author":"Dragoni F","year":"2018","unstructured":"Dragoni F, Chiarotti F, Iori AP, La Rocca U, Cafolla A. Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events. Thromb J. 2018, 16:26. 10.1186\/s12959-018-0181-5","journal-title":"Thromb J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188164","article-title":"Anticoagulation use and patient outcomes in paroxysmal nocturnal hemoglobinuria: a province-wide retrospective review","volume":"28","author":"Croden J","year":"2023","unstructured":"Croden J, Oliver M, Wu CM. Anticoagulation use and patient outcomes in paroxysmal nocturnal hemoglobinuria: a province-wide retrospective review. Blood. 2023, 28:1283. 10.1182\/blood-2023-188164","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024023988","article-title":"Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a\u00a02043-patient-year analysis","volume":"144","author":"Gurnari C","year":"2024","unstructured":"Gurnari C, Awada H, Pagliuca S, et al.. Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a\u00a02043-patient-year analysis. Blood. 2024, 144:145-55. 10.1182\/blood.2024023988","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1128994","article-title":"Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study","volume":"13","author":"Chatzileontiadou S","year":"2023","unstructured":"Chatzileontiadou S, Hatjiharissi E, Angelopoulou M, et al.. Thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): Real world data of a Greek nationwide multicenter retrospective study. Front Oncol. 2023, 13:1128994. 10.3389\/fonc.2023.1128994","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04933-5","article-title":"The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria","volume":"101","author":"Han B","year":"2022","unstructured":"Han B, Ji J, Zhang B, et al.. The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2022, 101:2537-9. 10.1007\/s00277-022-04933-5","journal-title":"Ann Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-022-00407-w","article-title":"Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia","volume":"20","author":"Bosi A","year":"2022","unstructured":"Bosi A, Barcellini W, Fattizzo B. Pulmonary embolism in a patient with eltrombopag-treated aplastic anaemia and paroxysmal nocturnal haemoglobinuria clone during COVID-19 pneumonia. Thromb J. 2022, 20:46. 10.1186\/s12959-022-00407-w","journal-title":"Thromb J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-016-1363-2","article-title":"Erratum to: pharmacology of anticoagulants used in the treatment of venous thromboembolism","volume":"42","author":"Nutescu EA","year":"2016","unstructured":"Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Erratum to: pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016, 42:296-311. 10.1007\/s11239-016-1363-2","journal-title":"J Thromb Thrombolysis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S204246","article-title":"Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study","volume":"13","author":"Ng DL","year":"2019","unstructured":"Ng DL, Gan GG, Chai CS, Chee KH, Tan KL, Tan SB, Bee PC. Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. Patient Prefer Adherence. 2019, 13:1363-73. 10.2147\/PPA.S204246","journal-title":"Patient Prefer Adherence"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros J","year":"2019","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, et al.. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019, 171:685-94. 10.7326\/M19-0291","journal-title":"Ann Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-133918","article-title":"Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories","volume":"112","author":"de Latour RP","year":"2008","unstructured":"de Latour RP, Mary JY, Salanoubat C, et al.. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008, 112:3099-106. 10.1182\/blood-2008-01-133918","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly RJ","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM, et al.. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011, 117:6786-92. 10.1182\/blood-2011-02-333997","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.06.008","article-title":"Alterations in markers of coagulation and fibrinolysis in patients with paroxysmal nocturnal hemoglobinuria before and during treatment with eculizumab","volume":"136","author":"van Bijnen ST","year":"2015","unstructured":"van Bijnen ST, \u00d8sterud B, Barteling W, Verbeek-Knobbe K, Willemsen M, van Heerde WL, Muus P. Alterations in markers of coagulation and fibrinolysis in patients with paroxysmal nocturnal hemoglobinuria before and during treatment with eculizumab. Thromb Res. 2015, 136:274-81. 10.1016\/j.thromres.2015.06.008","journal-title":"Thromb Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007308","article-title":"Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis","volume":"6","author":"Rozi W","year":"2022","unstructured":"Rozi W, Rahhal A, Ali EA, et al.. Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis. Blood Adv. 2022, 6:5061-6. 10.1182\/bloodadvances.2022007308","journal-title":"Blood Adv"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.439","article-title":"Anticoagulating patients with high-risk acquired thrombophilias","volume":"2018","author":"Skeith L","year":"2018","unstructured":"Skeith L. Anticoagulating patients with high-risk acquired thrombophilias. Hematology Am Soc Hematol Educ Program. 2018, 2018:439-49. 10.1182\/asheducation-2018.1.439","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/330133-direct-oral-anticoagulants-and-paroxysmal-nocturnal-hemoglobinuria-a-systematic-review-and-update-on-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T05:44:10Z","timestamp":1735710250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/330133-direct-oral-anticoagulants-and-paroxysmal-nocturnal-hemoglobinuria-a-systematic-review-and-update-on-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.76702","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}